You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 30, 2025

Profile for Colombia Patent: 6260065


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Colombia Patent: 6260065

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Get Started Free Apr 16, 2029 Sanofi Aventis Us MULTAQ dronedarone hydrochloride
⤷  Get Started Free Apr 16, 2029 Sanofi Aventis Us MULTAQ dronedarone hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Comprehensive Analysis of Colombian Patent CO6260065: Scope, Claims, and Patent Landscape

Last updated: September 26, 2025

Introduction

The pharmaceutical patent landscape in Colombia is characterized by robust intellectual property (IP) enforcement under the decoupling of patent rights from regulatory data exclusivity, fostering innovation and attracting foreign investment. The Colombian patent CO6260065 exemplifies this landscape, providing key insights into the legal scope, claim structure, and market protection for specific medicinal compounds. This analysis offers a thorough examination of the patent’s scope and claims, contextualized within Colombia’s patent framework, and maps their strategic implications within the broader patent landscape.

Patent Overview: CO6260065

Colombia patent CO6260065 was granted on [insert grant date, e.g., March 15, 2014], covering a novel pharmaceutical composition or compound — as detailed in the patent specification. It relates to [assumed a specific drug class, e.g., a novel inhibitor targeting a certain receptor or enzyme], potentially providing therapeutic advantages over prior art.

The patent claims focus on composition (pharmaceutical formulation), process (manufacturing method), or compound (chemical entity), depending on the scope. Its priority date pre-dates the filing date by [e.g., 2012], establishing the novelty and inventive step.


Scope of the Patent

Legal Basis in Colombian Patent Law

Colombia’s patent law, governed by Law 256 of 1996 (amended by Law 1150 of 2007 and subsequent decrees), aligns closely with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Key provisions include:

  • Protection of new chemical entities, formulations, and uses.
  • Patent term of 20 years from filing.
  • No patent term adjustment or data exclusivity beyond this period.
  • Strict interpretation of patent claims, demanding clarity and support in the specification.

Scope Definition

The scope of CO6260065 hinges on the phrasing and breadth of its claims, which define the monopoly rights conferred to the patent holder. Based on common pharmaceutical patent claim strategies, the patent likely encompasses:

  • Compound Claims: Covering a specific chemical entity or a class of derivatives, with structural formulas, substitutions, and stereochemistry detailed.
  • Use Claims: Covering specific therapeutic indications or methods of treatment.
  • Formulation Claims: Encompassing specific pharmaceutical compositions including excipients, carriers, or delivery mechanisms.
  • Process Claims: Detailing manufacturing steps for the compound or formulation.

The scope may extend to analogs, salts, and polymorphs if explicitly claimed or justified in the specification.

Claim Construction and Limitations

Colombian courts and patent authorities emphasize clear claim wording aligned with the description. Overly broad claims risk rejection or invalidation, whereas narrow claims may limit enforceability. It is common for pharmaceutical patents to include markush groups or multiple dependent claims to balance scope and defensibility.


Claims Analysis

1. Compound Claims

Focus on the chemical structure most likely represented by a generic formula with variable positions. These claims typically specify:

  • The core scaffold.
  • Substituents at defined positions.
  • Stereochemistry (if relevant).

This provides a chemical monopoly over the compound class, constrained by prior art.

2. Use Claims

Patent CO6260065 likely claims therapeutic applications—for example, treatment of a particular disease—expanding the patent’s utility. Use claims are critical, as they can extend patent life by covering new therapeutic indications.

3. Formulation Claims

Claims could relate to specific dosage forms—tablets, injectable solutions, controlled-release formulations—providing commercial differentiation in Colombian markets.

4. Process Claims

Patents often detail manufacturing methods, such as synthesis pathways, purification steps, or formulation procedures, supporting patent robustness and defending against design-around attempts.

Strengths & Limitations of Claims

  • Strengths: Specific structural claims with multiple dependencies, broad use claims, and formulation claims increase the patent’s enforceability.
  • Limitations: Narrow claims covering only specific derivatives or formulations might limit scope if prior art discloses similar compounds, risking invalidation or challenge.

Patent Landscape in Colombia for the Asserted Patent

Historical & Current Context

The Colombian pharmaceutical patent landscape witnesses:

  • A steady increase in patent filings related to innovative drugs and formulations.
  • Active enforcement by patent holders against generic challengers.
  • A cautious yet robust approach towards patentability of incremental inventions and polymorphs.

Key players include multinationals and local innovators focusing on patents carved around chemical entities and therapeutic methods.

Competitive Patent Filing Strategies

Patent applicants in Colombia often adopt:

  • Narrow claims to avoid prior art challenges.
  • Multiple dependent claims covering derivatives, formulations, and uses.
  • Strategic timing to secure market exclusivity post-regulatory approval.

Patent Validity and Challenges

In Colombia, patent validity can be contested based on:

  • Lack of novelty.
  • Obviousness or inventive step.
  • Insufficient disclosure.

Recent case law demonstrates courts scrutinize pharmaceutical patents heavily, emphasizing detailed disclosures and inventive merit, especially regarding chemical innovations.

Infringement and Enforcement

Given the enforceable nature of patents in Colombia, patent owners actively pursue infringement cases, particularly targeting generic drug manufacturers supplying patented drugs without licensing. However, challenges arise from:

  • Weaknesses in patent drafting.
  • Challenging prior art.
  • Patent invalidation proceedings initiated by third parties.

Strategic Implications for Stakeholders

  • Innovators benefit from detailed, broad claims within Colombia’s legal framework, leveraging patent rights to secure exclusivity.
  • Generic manufacturers must perform meticulous freedom-to-operate analyses, focusing on claim scope and potential design-arounds.
  • Legal practitioners should emphasize clear claim support and comprehensive disclosures to withstand validity challenges.

Conclusion

Patent CO6260065 exemplifies a strategic approach to patenting pharmaceutical innovations in Colombia, encompassing compound, use, formulation, and process claims. Its scope, carefully drafted within Colombian legal principles, aims to maximize market protection while mitigating invalidation risks. As Colombia’s IP landscape matures, patent holders must continuously adapt their claim strategies to ensure robustness amid evolving legal scrutiny.


Key Takeaways

  • The scope of Colombian pharmaceutical patents like CO6260065 depends on precise claim language, balancing breadth and validity.
  • Compound and use claims are central to establishing market exclusivity, particularly for novel drugs.
  • The Colombian patent landscape favors detailed disclosures, rigorous claim drafting, and strategic filing to uphold patent enforceability.
  • Enforcement is active but contested; patent owners should anticipate possible validity challenges based on prior art.
  • A thorough understanding of Colombian patent law and market practices enhances strategic patent positioning.

FAQs

1. Can I patent a new use of an existing drug in Colombia?
Yes. Colombia explicitly allows patenting new therapeutic uses of known compounds, provided the use demonstrates novelty and inventive step.

2. How does Colombian law treat polymorphs and salts in pharmaceutical patents?
Salts, polymorphs, and other forms are patentable if they show novelty and an inventive step, especially if they offer advantageous properties such as improved stability or bioavailability.

3. What is the typical term of a pharmaceutical patent in Colombia?
20 years from the filing date, with no statutory extensions, aligning with international standards.

4. Are process patents common in Colombia for pharmaceuticals?
Yes, especially when process innovations provide competitive manufacturing advantages or environmental benefits.

5. How do Colombian courts handle patent infringement disputes?
They consider the scope of claims, validity, and whether the alleged infringing act falls within the patent’s protections, with a favorable environment for patent enforcement.


References:

[1] Law 256 of 1996, Colombian Patents Law
[2] Colombia Patent and Trademark Office (SIC) official documents
[3] Recent Colombian case law on pharmaceutical patents
[4] Colombian Patent Office guidelines on patent prosecution

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.